Value of diffusion-weighted imaging for evaluating chemotherapy response in osteosarcoma: A meta-analysis
- PMID: 28685082
- PMCID: PMC5492712
- DOI: 10.3892/mco.2017.1273
Value of diffusion-weighted imaging for evaluating chemotherapy response in osteosarcoma: A meta-analysis
Abstract
The histological examination of the tumor necrosis upon surgery remains the most reliable prognostic factor for osteosarcoma. However, the detection of more early prognostic factors is desirable in order to increase the survival rates and decrease the risk rates for iatrogenic toxicity. The purpose of the current systematic review and meta-analysis was to provide an up-to-date summary of the role of diffusion-weighted imaging (DWI) for the preoperative assessment of the chemotherapy response in osteosarcoma. Articles evaluating DWI for the preoperative assessment of the chemotherapy response of osteosarcoma were systematically searched for in four electronic literature databases. The mean difference in apparent diffusion coefficient (ADC) following neoadjuvant chemotherapy between good and poor histological responders was assessed in 5 studies. The mean difference in the ADC ratio (the percentage change in ADC between post-neoadjuvant and pre-neoadjuvant chemotherapy) reported in 3 studies was also assessed. Five articles with 106 patients fulfilled all of the inclusion criteria for the meta-analysis. Significant mean differences were found between good and poor responders in the ADC in the 5 studies (P=0.03) and the ADC ratio in the 3 studies (P<0.00001). The good responders demonstrated a higher ADC and a higher ADC ratio than the poor responders. DWI performed with ADC values was useful for predicting the chemotherapeutic response of osteosarcoma. This method may have promising potential as a preoperative non-invasive modality.
Keywords: apparent diffusion coefficient; chemotherapy response; diffusion-weighted imaging; meta-analysis; osteosarcoma.
Figures



Similar articles
-
Efficacy of Diffusion-Weighted Imaging in Neoadjuvant Chemotherapy for Osteosarcoma: A Systematic Review and Meta-Analysis.Acad Radiol. 2022 Feb;29(2):326-334. doi: 10.1016/j.acra.2020.11.013. Epub 2020 Dec 30. Acad Radiol. 2022. PMID: 33386220
-
Noninvasive assessment of response to neoadjuvant chemotherapy in osteosarcoma of long bones with diffusion-weighted imaging: an initial in vivo study.PLoS One. 2013 Aug 26;8(8):e72679. doi: 10.1371/journal.pone.0072679. eCollection 2013. PLoS One. 2013. PMID: 23991141 Free PMC article.
-
Diffusion-weighted imaging in differentiating mid-course responders to chemotherapy for long-bone osteosarcoma compared to the histologic response: an update.Pediatr Radiol. 2021 Aug;51(9):1714-1723. doi: 10.1007/s00247-021-05037-4. Epub 2021 Apr 20. Pediatr Radiol. 2021. PMID: 33877417 Free PMC article.
-
[Application of apparent diffusion coefficient combined with serum tumor markers detection in evaluating neoadjuvant chemotherapy for osteosarcoma].Zhonghua Yi Xue Za Zhi. 2020 Apr 7;100(13):1012-1016. doi: 10.3760/cma.j.cn112137-20190722-01625. Zhonghua Yi Xue Za Zhi. 2020. PMID: 32294859 Chinese.
-
Diffusion-weighted imaging for determining response to neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis.Eur Radiol. 2024 May;34(5):3238-3248. doi: 10.1007/s00330-023-10381-0. Epub 2023 Nov 1. Eur Radiol. 2024. PMID: 37907761 Free PMC article.
Cited by
-
Pediatric skeletal diffusion-weighted magnetic resonance imaging, part 2: current and emerging applications.Pediatr Radiol. 2021 Aug;51(9):1575-1588. doi: 10.1007/s00247-021-05028-5. Epub 2021 May 21. Pediatr Radiol. 2021. PMID: 34018037 Review.
-
Multiparametric MRI with diffusion-weighted imaging in predicting response to chemotherapy in cases of osteosarcoma and Ewing's sarcoma.Br J Radiol. 2020 Nov 1;93(1115):20200257. doi: 10.1259/bjr.20200257. Epub 2020 Oct 15. Br J Radiol. 2020. PMID: 32706980 Free PMC article.
-
Non-invasive intravoxel incoherent motion MRI in prediction of histopathological response to neoadjuvant chemotherapy and survival outcome in osteosarcoma at the time of diagnosis.J Transl Med. 2022 Dec 27;20(1):625. doi: 10.1186/s12967-022-03838-1. J Transl Med. 2022. PMID: 36575510 Free PMC article.
-
Imaging biomarkers for evaluating tumor response: RECIST and beyond.Biomark Res. 2021 Jul 2;9(1):52. doi: 10.1186/s40364-021-00306-8. Biomark Res. 2021. PMID: 34215324 Free PMC article. Review.
-
Alkaline phosphatase, lactic dehidrogenase, inflammatory variables and apparent diffusion coefficients from MRI for prediction of chemotherapy response in osteosarcoma. A cross sectional study.Ann Med Surg (Lond). 2021 Mar 16;64:102228. doi: 10.1016/j.amsu.2021.102228. eCollection 2021 Apr. Ann Med Surg (Lond). 2021. PMID: 33777392 Free PMC article.
References
-
- Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M, Winkelmann W, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: An analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002;20:776–790. doi: 10.1200/JCO.20.3.776. - DOI - PubMed
-
- Lewis IJ, Nooij MA, Whelan J, Sydes MR, Grimer R, Hogendoorn PC, Memon MA, Weeden S, Uscinska BM, van Glabbeke M, et al. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: A randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst. 2007;99:112–128. doi: 10.1093/jnci/djk015. - DOI - PubMed
-
- Eselgrim M, Grunert H, Kühne T, Zoubek A, Kevric M, Bürger H, Jürgens H, Mayer-Steinacker R, Gosheger G, Bielack SS. Dose intensity of chemotherapy for osteosarcoma and outcome in the Cooperative Osteosarcoma Study Group (COSS) trials. Pediatr Blood Cancer. 2006;47:42–50. doi: 10.1002/pbc.20608. - DOI - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources